Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for CancerDonghai Xiong, Ming You, Yian Wang et al.|iScience|2018Cited by 103
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical PracticeLindsey E. Roeker, Anthony R. Mato, John N. Allan et al.|Clinical Cancer Research|2019Cited by 90